Cytochalasin D |
0.1 μg/mL for 48 h |
ALP and calcium levels decreased at days 5 and 10 |
[29] |
Cytochalasin D |
100 ng/mL for 1, 3, 7, and 14 days |
Decreased levels of ALP and osteocalcin, increased levels of adiponectin and peroxisome proliferator-activated receptor gamma (PPARG) |
[16] |
Cytochalasin D |
0.02 mg/mL |
Increased adipogenesis |
[83] |
Cytochalasin D |
1–20 μM, 1 h every day for 9 days |
Decreased osteoblast differentiation, decreased ALP and mineral matrix |
[55] |
Phalloidin |
0–6 μM, 3 h every day for 9 days |
Increased ALP activity and mineralized matrix formation |
|
Cytochalasin D |
0.1 mg/mL day 1 |
Osterix, osteocalcin, and Runt-related transcription factor 2 (RUNX2) levels increased on days 2 and 3 |
[84] |
Cytochalasin D |
0.1 mg/mL for 3 days |
Increase in osteogenesis (higher level of alkaline phosphatase, tissue-nonspecific isozyme (Alpl), specificity protein (Sp7), gamma-carboxyglutamic acid-containing protein (Bglap genes)) and adipogenesis (higher level of fatty acid-binding protein (FABP4), adiponectin gene (ADIPOQ), and peroxisome proliferator-activated receptor γ (PPARγ genes)) in growth medium, increased adipogenesis in adipogenic medium, and increases osteogenesis in osteogenic medium |
[57] |
Cytochalasin D |
0.1 mg/mL for 14 days |
Increase in osteogenesis through increased expression of the VGLL4 gene; the effect of cytochalasin D was dependent on the biological state of the cells |
[85] |
Cytochalasin D |
1–20 μM for 1 h every day for 13 days |
Increased adipocyte differentiation |
[49] |
Phalloidin |
0–3 μM for 3 h every day for 13 days |
Decreased adipocyte differentiation and adipocyte-specific gene expression (ADIPOQ, LPL, PPARG, FABP4) |
[49] |
Cytochalasin D |
– |
Increased adipogenesis through the regulation of the FGF2, TGFβ2, EGR2, MEF2D, and IRS1 genes |
[56] |